UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date
Industry Concerned Over Market Access As Five-Year Deal Reaches Half-Way Mark
Executive Summary
Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.